Uncovering Potential: Enhabit's Earnings Preview
Enhabit (NYSE:EHAB) is set to give its latest quarterly earnings report on Wednesday, 2026-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Enhabit will report an earnings per share (EPS) of $0.14.
The announcement from Enhabit is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Overview of Past Earnings
During the last quarter, the company reported an EPS beat by $0.05, leading to a 6.09% drop in the share price on the subsequent day.
Here's a look at Enhabit's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.12 | 0.10 | 0.06 | 0.05 |
| EPS Actual | 0.17 | 0.13 | 0.10 | 0.04 |
| Price Change % | -6.09 | 15.21 | 18.17 | -6.09 |
Tracking Enhabit's Stock Performance
Shares of Enhabit were trading at $13.58 as of March 02. Over the last 52-week period, shares are up 59.07%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Discovering Enhabit: A Closer Look
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
Enhabit: Financial Performance Dissected
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Enhabit's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 3.94%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Enhabit's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.21%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enhabit's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.9%, the company showcases effective utilization of assets.
Debt Management: Enhabit's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
To track all earnings releases for Enhabit visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.